Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults. Phentermine hydrochloride.Īronne LJ, Wadden TA, Peterson C, Winslow D, Odeh S, Gadde K. Naltrexone/bupropion (Contrave) for weight loss. The current role of liraglutide in the pharmacotherapy of obesity. Liraglutide (Saxenda) as a treatment for obesity. Phentermine and topiramate extended release (Qsmia). Phentermine/topiramate (Qsmia) for chronic weight management. Clinical utility of phentermine/topiramate (Qsmia) combination for the treatment of obesity. Pharmacotherapy for obesity: What you need to know. The challenge of obesity treatment: a review of approved drugs and new therapeutic targets. doi:10.1111/ijcp.13399įrancisco Bonamichi B, Bezerra Parente E, dos Santos R, Beltzhoover R, Lee J, Nunes Salles J. Effectiveness and tolerability of orlistat and liraglutide in patients with obesity in a real-world setting: The XENSOR Study. Basagoiti-Carreno B, Sanz-Velasco A, Serrano-Moreno C, Almodovar-Ruiz F. Orlistat (marketed as Alli and Xenical) Information. Sibutramine effects on central mechanisms regulating energy homeostatis. Unapproved pharmaceutical ingredients included in dietary supplements associated with US Food and Drug Administration warnings. Prescription medications to treat overweight and obesity.
National Institute of Diabetes and Digestive and Kidney Diseases.
0 kommentar(er)
